News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
05 Jul 2023
byChristina Lau
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.
05 Jul 2023

ADHD meds emerge as preferred option for reducing self-harm risk in BPD
04 Jul 2023
byJairia Dela Cruz
For individuals with bipolar disorder (BPD), attention-deficit/hyperactive disorder (ADHD) medications help lower the risk of suicidal behaviour, according to data from a comparative effectiveness research study.
04 Jul 2023






